Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
Portfolio Pulse from Lara Goldstein
Cybin (NYSE:CYBN) has received three new international patents for its deuterated psychedelics programs, two from the United States Patent and Trademark Office and one from the European Patent Office. The patents protect the composition of matter for certain deuterated DMT analogs and their medical use. The company's development programs are now protected by 33 granted patents and over 170 pending applications. Cybin is currently conducting Phase 1 clinical trials for its deuterated DMT compounds CYB004 and SPL028, and a Phase 2 clinical trial for its deuterated psilocybin analog CYB003.
October 26, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin has received three new international patents for its deuterated psychedelics programs. The company's development programs are now protected by 33 granted patents and over 170 pending applications.
The new patents provide Cybin with protection for its deuterated psychedelics programs, which could potentially give the company a competitive advantage in the market. This could lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Small Pharma (OTC:DMTTF), recently acquired by Cybin, is indirectly affected by the new patents granted to Cybin's deuterated psychedelics programs.
As a company recently acquired by Cybin, Small Pharma is indirectly affected by the new patents granted to Cybin. The patents could potentially enhance the value of Small Pharma's assets under Cybin, which could have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50